Understanding structure-function relationships is crucially important in controlling glaucoma.
Progress occurring on several fronts is creating optimism that retinal ganglion cell (RGC) replacement may become a reality for preserving or restoring vision in patients with glaucoma, according to Jeffrey L. Goldberg, MD, PhD.
Optometry Times Chief Optometric Editor Benjamin P. Casella, OD, FAAO, discusses how exercises including yoga impact patients who have glaucoma.
How much the lamina cribrosa curves inward could become a useful prognostic factor in glaucoma.
As more microinvasive glaucoma surgery (MIGS) procedures become available, surgeons are faced with decisions on adoption of new techniques.
Two new glaucoma drugs approved in late 2017 are not on the 2018 Medicare Part D formulary, creating quandaries for physicians who would like to prescribe them and for patients who may have to pay out of pocket.
Glaucoma specialists need to ask if cerebrospinal fluid (CSF) pressure in glaucoma matters, and if so, why, according to John Berdahl, MD.
Results from MERCURY-1, a 12-month phase III pivotal trial, show that once daily treatment with fixed-dose combination netarsudil 0.02%/latanoprost 0.005% (Aerie Pharmaceuticals) is safe and provided significantly greater IOP-lowering than either of its components throughout follow-up.
In a small study, a combination over-the-counter supplement with antioxidant and mitoprotective properties significantly reversed mitochondrial dysfunction.
Jonathan S. Myers, MD, reports that intraocular drug delivery systems could help solve the problem of poor adherence in patients taking glaucoma medications. Implanted in the eye, the systems would allow for glaucoma drugs to gradually dissolve or elute medication.